Clinical Updates on Immune-directed Therapies for MS: Expert Insights & Real World Evidence
Presented at the ACTRIMS 2020 Forum
May 1, 2020 – April 30, 2021
Archived, for viewing purposes only.
Recent advances in the field of immunology and the increasing recognition of inflammatory pathways are re-shaping the conceptualization of multiple sclerosis (MS), with potential implications of new agents within the current landscape of treatment options. This online CME/CNE activity features clinician/researchers who will provide expert insights and updated evidence for immune-directed strategies in MS. Their presentations will describe the rationale for immune system reset along with supporting clinical evidence, and identify risks and benefits of current and emerging DMTs, including understanding of complications (i.e., infections, malignancy potential), as well as strategies for optimizing sequencing of therapies in individualized MS patient care.
After participating in this accredited satellite symposium, the learner should be able to:
- Describe critical advances and emerging immune-directed therapies that will change the therapeutic approach to MS;
- Review the immunologic rationale, safety, and clinical efficacy of supporting an immune system reset;
- Identify clinical considerations when evaluating risks and benefits in deciding on DMT therapy;
- Summarize the concept of immunosenescence and the importance of vigilance in monitoring the risk of infections especially in older MS patients;